Human Growth Hormone Market Analysis , Innovation Trends and Current Business Trends by By 2025 : Grand View Research Inc

Spread the love

San Francisco, United States, 2019-May-06 — /EPR Network/ —

The global human growth hormone (hGH) market is expected to reach USD 7.1 billion by 2025, according to a new report by Grand View Research, Inc. Rising cases of pituitary dysfunction and increasing use of human growth hormone are likely to drive the market in coming years.

Turner syndrome, growth hormone deficiency, Prader-Willi syndrome, idiopathic short stature, and small for gestational age (SGA) are major disorders in which growth hormone (GH) are used. Additionally, growth hormone also received an approval for other indications such as Creutzfeldt-Jakob disease, chronic kidney disease, SHOX gene haploinsufficiency, and Noonan syndrome.

Although FDA has not approved the use of hGH as anti-aging therapy, many practitioners offer injections of growth hormones at higher prices. The hGH therapy is aggressively promoted for advanced age symptoms.

hGH is anabolic as it accelerates protein synthesis and breaks down fat. Hence, athletes involved in strength demanding activities and sports are likely to use growth hormones for its anabolic effects. It is a fairly common practice among athletes and body-builders to use combination of anabolic steroids and GH for the benefits.

To request a sample copy or view summary of this report, click the link below:

Further Key Findings From the Report Suggest:

  • Increasing demand for hGH due to rising growth hormone deficiency diseases and technological advancement such as recombinant DNA technology are expected to propel the market growth.
  • The growth hormone deficiency segment accounted for the highest share of the market in 2016 and is estimated to observe the fastest growth of the market. This can be attributed to increasing incidence of pituitary dysfunctioning and investment by major players for the research and development of human growth hormone drugs.
  • Turner syndrome also accounted for the significant share in the GH market. Large number of patients and effectivity of growth hormone to treat Turner’s syndrome are the key reasons for the significant share in the market.
  • Geographically, North America was the largest market for GH in 2016 and is anticipated to maintain its dominance during the forecast period due to the local presence of market players, the presence of strong pipeline, and affordability of hormonal therapy.
  • Asia Pacific is estimated to witness the fastest growth during the forecast period owing to increasing healthcare expenditure, investment by market players, and large patient pool. Furthermore, increasing awareness about the therapy for short stature is likely to boost the demand for GH.
  • Some of the key players are Pfizer, Inc.; Merck & Co., Inc.; Eli Lilly and Company, Genentech, Inc., Novo Nordisk, Sandoz International GmbH, Ferring Holding SA, and Ipsen.

Global human growth hormone market

Application Insights

By application, the market has been segmented into growth hormone deficiency, Idiopathic Short Stature (ISS), Turner syndrome, Prader-Willi syndrome, Small for Gestational Age (SGA), and others. In 2016, growth hormone deficiency segment accounted for the largest market share and is expected to maintain its dominance during the forecast period.

Adult Growth Hormone Deficiency (AGHD) is increasing due to several factors such as pituitary tumors, neuropsychiatric-cognitive, neuromuscular, cardiovascular, skeletal abnormalities and metabolic abnormalities. Most of these disorders can be reversed with growth hormone therapy. It is expected that in the adult UK population at any given time, about one in every 10,000 people will have an adult onset growth hormone deficiency.

Turner syndrome accounted for the second largest share of the GH market in 2016 due to their ability to treat delayed physical as well as sexual development. The U.S. FDA approved hGH as standard treatment for Turner syndrome in 1996. Common brands of GH used to treat Turner syndrome include Humatrope, Genotropin, and Nutropin.

Creutzfeldt-Jakob disease, SHOX gene haploinsufficiency, chronic renal insufficiency, skeletal dysplasia, Down syndrome, and Noonan syndrome are other indications for which growth hormone therapy is approved in various countries. Expansion of indications is expected to boost the other segment market growth in coming years.

Regional Insights

North America dominated the global market in 2016 and accounted for around 48.0%. This can be attributed to affordability for costly medicine, the presence of pipeline, local presence of market players, and commercialization of GH by the U.S.FDA since last few years.

Asia Pacific is anticipated to witness the fastest growth during the forecast period as the demand for GH is rising in the emerging countries for the past few years. Japan, Australia, China, and India are the major contributing countries in the region. Investment by market players in the region due to the growing demand is one of the major factors for the market growth. For instance, in March 2017, Novo Nordisk initiated phase 3 clinical trial of somapacitan (NNC0195-0092) for AGHD using Norditropin as comparator in Japan.

Presence of large patient pool in the Asia Pacific region and increasing awareness about the effectivity of the GH is anticipated to boost the market in coming years. Japan accounted for the largest share of the market in 2016 due to high cost of the GH and local presence of market players.

Competitive Insights

The hGH market is consolidated in nature. Major players operating in the market are Eli Lilly and Company, Ferring Holding SA, Genentech, Inc., Merck & Co., Inc.; Novo Nordisk, Pfizer, Inc.; Sandoz International GmbH, and Ipsen.

Investment for the development of effective & long-acting products with lesser adverse effects and improving geographic penetration through partnerships and collaborations are the key strategies adopted by the companies to increase their market share. For instance, in December 2014, Pfizer entered into an agreement with OPKO for development and commercialization of human growth hormone hGH-CTP for treatments in children and adults.

In January 2015, Novo Nordisk received U.S. FDA approval for Norditropin FlexPro, an injection pen for patients with disorders related to growth hormones.

Comment here

Enter Captcha Here : *

Reload Image